Company intelligence / Profile preview
ReviR Therapeutics
Brisbane, California, United Statesrevirtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ReviR Therapeutics is developing RNA-targeting small molecule therapies using AI technology. The company recently raised $30 million in Series A financing to advance its proprietary oral genetic medicines for multiple CNS disorders. No specific clinical results were mentioned in the search results.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- RNA-targeting small moleculesoral genetic medicines
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ReviR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReviR Therapeutics.